Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Inclusion Criteria: * Voluntarily understand and sign the informed consent form for this study. * Age ≥ 18 years, male or female. * Histologically or cytologically confirmed thoracic ESCC (Stage T1-2N1-2M0 or T3N0-2M0, according to the AJCC 8th edition). * ECOG performance status of 0-2. * No prior treatment for esophageal squamous cell carcinoma. * Life expectancy ≥ 3 months. * Adequate function of major organs within 7 days before the first treatment (use of any blood components or cell growth factors within 14 days before enrollment is not permitted):Hemoglobin ≥ 90 g/L; White blood cell count ≥ 3.5 × 10\^9/L; Absolute neutrophil count ≥ 1.5 × 10\^9/L; Platelets ≥ 80 × 10\^9/L; AST and ALT ≤ 2.5 × ULN; Total bilirubin (TBIL) ≤ 1.5 × ULN; Blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5 × ULN (and creatinine clearance (CCr) ≥ 50 mL/min); Left ventricular ejection fraction (LVEF) ≥ 50%. * Fertile patients must agree to use reliable contraceptive methods with their partner during the trial and for at least 180 days after the last dose. Exclusion Criteria: * Inability to comply with the study protocol or study procedures. * Presence of supraclavicular lymph node metastasis. * Obvious tumor invasion of organs adjacent to the esophageal lesion. * Evidence of esophagomediastinal or tracheoesophageal fistula found on imaging within 4 weeks before enrollment. * Allergy or known hypersensitivity to the study drugs or their excipients. * Anticipated need for systemic corticoste…